BMC Biotechnology
Call for papers: Role of Synthetic Biology and Gene Engineering in CAR Immunotherapy
BMC Biotechnology is currently accepting submissions to a thematic series entitled ' Role of Synthetic Biology and Gene Engineering in CAR Immunotherapy'.
Chimeric antigen receptor (CAR) T cells therapies, as a cancer immunotherapy, have provided significant benefit in treating cancer.
To present the recent advances in the theory and application of CAR immunotherapy, we invite you and/or members of your research team to provide a manuscript for this thematic series.
Your submission could take the form of original research, review, or commentary.
Deadline for submission to the collection: 30th June 2018
Articles
- RESEARCH ARTICLE
- RESEARCH ARTICLE
- METHODOLOGY ARTICLE
An att site-based recombination reporter system for genome engineering and synthetic DNA assembly
Published on: 14 July 2017 - METHODOLOGY ARTICLE
Overview of methodologies for T-cell receptor repertoire analysis
Published on: 10 July 2017 - RESEARCH ARTICLE
Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice
Published on: 4 July 2017
No hay comentarios:
Publicar un comentario